Bibliography (PubMed)

Transcription

1 Bibliography (PubMed) Prof. Dr. med. Hans-Joachim Schmoll N Publications total: 420 Impact Factor (cumulative): 1807,55 Citation-Factor (Hirsch) : 64 No. of Publications per year ( ) No. of Citations per year ( )

2 Bibliography according to PubMed with Impact Factor Prof.Dr.med.habil. Hans-Joachim Schmoll 1. Schwoon DR, Schmoll HJ: (1979) Motivation to participate in cancer screening programmes. SOC SCI MED, 13: IF: 2,742, anteiliger IF: 1, Summe Bewertung = 1,371 Summe IF = 2, Schmoll HJ, Niederle N, Achterrath W: (1981) [Etoposide VP )--a podophyllotoxinderivative with high antitumor activity (author's transl)]. KLIN WOCHENSCHR, 59: IF: 0,809, anteiliger IF: 0, Summe Bewertung = 0,2697 Summe IF = 0, Freise J, Mueller WH, Magerstedt P, Schmoll HJ (1982) Pharmacokinetics of liposome encapsulated cisplatin in rats. ARCH INT PHARMACODYN THER 258: IF: 2,103, anteiliger IF: 0, Schmoll H.(1982) Review of etoposide single-agent activity. Cancer Treat Rev. Jun;9 Suppl: IF: 4,7 anteiliger IF: 4,7 5. Schindler E, Waegner W, Schmoll H, Zockler H.. [Role of lymphadenectomy in stages I and II of non-seminoma tumors. Report of their modern chemotherapy (author's transl)]. J Urol (Paris). 1982;88(5):295-9 IF: 1,91 anteiliger IF: 0, Summe Bewertung = 5,71933 Summe IF = 8, Weiss J, von Roemeling R, Peters HD, Schmoll HJ, Diehl V: (1983) [Chemotherapy in pretreated Hodgkin's disease with lomustine, bleomycin, vinblastine and dexamethasone]. Dtsch Med Wochenschr, 108: IF: 0,528, anteiliger IF: 0,0587

3 7. Hacke M, Schmoll HJ, Alt JM, Baumann K, Stolte H (1983) Nephrotoxicity of cisdiamminedichloroplatinum with or without ifosfamide in cancer-treatment. Clin. Physiol. Biochem., 1: IF: 1,213, anteiliger IF: 0, Summe Bewertung = 0,26087 Summe IF = 1, Klose E, Ritter EP, Massopust D, Endert G, Schumann E, Hasse P, Schmoll H, Beyer HK. [Exposure technics for computed scintigrams]. Rofo Jul;141(1):97-9. IF: 1,005 anteiliger IF:0, Summe Bewertung = 0,05584 Summe IF = 1, Gabius HJ, Engelhardt R, Casper J, Reile D, Schumacher S, Schmoll HJ, Graupner G, Cramer F: (1985) Cell surface lectins of transplantable human teratocarcinoma cells: purification of a new mannan-specific endogenous lectin. TUMOR BIOL, 6: IF: 2,143, anteiliger IF: 0, Summe Bewertung = 0,1906 Summe IF = 2, Gabius HJ, Engelhardt R, Casper J, Schmoll HJ, Nagel GA, Cramer F: (1986) Comparison of endogenous lectins in human embryonic carcinoma and yolk sac carcinoma. TUMOR BIOL, 6: IF: 2,143, anteiliger IF: 0, Peest D, Schmoll HJ, Schedel I, Deicher H, Boll J, Essers U, Gamm H, Gluck S, Gorg K, Gramatzki M, et A: (1986) Current results of a multicenter trial in multiple myeloma. Onkologie, 9: IF: 0,868, anteiliger IF: 0, Summe Bewertung = 3,011 Summe IF = 0, Berdel WE, Berger MR, Falk H, Harstrick A, Danhauser S, Schick HD, Schmoll HJ, Schmahl D, Vogler WR, Rastetter J: (1987) Lack of therapeutic activity of the lipoidal amine CP-46,665 in rodent tumors and human non-seminomatous germ cell tumors growing in nude mice. CANCER LETT, 38: IF: 4,238, anteiliger IF: 0,17658

4 13. Casper J, Schmoll HJ, Schnaidt U, Fonatsch C: (1987) Cell lines of human germinal cancer. INT J ANDROL, 10: IF: 3,519, anteiliger IF: 0, Creutzig A, Polking W, Schmoll HJ, Fabel H, Alexander K: (1987) [Raynaud syndrome and changes in lung function as sequelae of cytostatic therapy of testicular tumors]. Med Klin Intensivmed Notfmed, 82: IF: 0,343, anteiliger IF: 0, Gabius HJ, Bokemeyer C, Hellmann T, Schmoll HJ: (1987) Targeting of neoglycoprotein-drug conjugates to cultured human embryonal carcinoma cells. J CANCER RES CLIN, 113: IF: 2,558 anteiliger IF: 0, Harstrick A, Casper J, Schmoll HJ: (1987) Comparative antitumour activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts. INT J ANDROL, 10: IF: 3,591, anteiliger IF: 1, Schmoll HJ, Schubert I, Arnold H, Dolken G, Hecht T, Bergmann L, Illiger J, Fink U, Preiss J, Pfreundschuh M, et A: (1987) Disseminated testicular cancer with bulky disease: results of a phase-ii study with cisplatin ultra high dose/vp-16/bleomycin. INT J ANDROL, 10: IF: 3,591, anteiliger IF: 1, von Wussow P, Freund M, Block B, Diedrich H, Schmoll H, Poliwoda H, Deicher H. [Low-dose alpha-interferon treatment of hairy cell leukemia]. Klin Wochenschr Jul 15;65(14): IF: 0,1 anteiliger IF: 0, Summe Bewertung = 4,05464 Summe IF = 17, Calavrezos A, Koschel G, Husselmann H, Taylessani A, Heilmann HP, Fabel H, Schmoll HJ, Dietrich H, Hain E: (1988) Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from KLIN WOCHENSCHR, 66: IF: 0,809 anteiliger IF: 0, Peest D, Schmoll HJ, Schedel I, Gluck S, Schumacher K, Deicher H: (1988) VBAMDex chemotherapy in advanced multiple myeloma. EUR J HAEMATOL, 40: IF: 2,004, anteiliger IF: 0,167

5 21. Verbeek W, Bokemeyer C, Falk H, Schmoll HJ: (1988) Growth requirements, growth factor responsiveness, and growth factor secretion of three human embryonal carcinoma cell lines. J CANCER RES CLIN, 114: IF: 2,558 anteiliger IF: 0, Wilke H, Achterrath W, Schmoll HJ, Gunzer U, Preusser P, Lenaz L: (1988) Etoposide and split-dose cisplatin in small-cell lung cancer. AM J CLIN ONCOL-CANC, 11: IF: 2,002 anteiliger IF: 0, Wilke H, Schmoll HJ, Preusser P, Fink U, Stahl M, Schober C, Link H, Freund M, Hanauske A, Meyer HJ, et A: (1988) Folinic acid (CF)/5-fluorouracil (FUra) combinations in advanced gastrointestinal carcinomas. ADV EXP MED BIOL, 244: IF: 1,093 anteiliger IF: 0, Wilke H, Schmoll HJ, Schober C, Stahl M, Preusser P, Freund M, Poliwoda H: (1988) Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer. BIOMED PHARMACOTHER, 42: IF: 2 anteiliger IF: 0, Peest D, Deicher H, Coldewey R, Schmoll HJ, Schedel I (1988) Induction and maintenance-therapy in multiple myeloma: A multicenter trial of MP vs. VCMP. EUR J CANCER CLIN ONCOL, 24: IF: 5,536 anteiliger IF: 0, Summe Bewertung = 2,0258 Summe IF = 16, Arnemann J, Gradl G, Casper J, Schmoll HJ, Schmidtke J, Fonatsch C: (1989) Characterization of rearranged Y chromosomes in human testicular tumor cell lines. CANCER GENET CYTOGEN, 37: IF: 1,389, anteiliger IF: 0, Bokemeyer B, Grote R, Schmoll E, Freise J, Schmoll HJ, Galanski M, Schuler A, Schmidt FW: (1989) [Chemoembolization of hepatocellular carcinoma with lipiodol, epirubicin and cisplatin]. Dtsch Med Wochenschr, 114: IF: 0,528 anteiliger IF: 0, Harstrick A, Casper J, Guba R, Wilke H, Poliwoda H, Schmoll HJ: (1989) Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro. CANCER-AM CANCER SOC, 63: IF: 4,771 anteiliger IF: 1, Schmoll HJ: (1989) The role of ifosfamide in testicular cancer. SEMIN ONCOL, 16(1 Suppl 3):

6 IF: 3,5 anteiliger IF: 3,5 30. Winkler K, Torggler S, Beron G, Bode U, Gerein V, Jurgens H, Kusnierz-Glaz C, Kotz R, Salzer-Kuntschik M, Schmoll HJ, et A: (1989) [Results of treatment in primary disseminated osteosarcoma. Analysis of the follow-up of patients in the cooperative osteosarcoma studies COSS-80 and COSS-82]. Onkologie, 12: IF: 0,173 anteiliger IF: 0, Meyer HJ, Jahne J, Pichlmayr R, Wilke H, Schmoll HJ, Poliwoda H (1989) Interdisciplinary therapy concepts in gastrointestinal tumors: Stomach. Z Gastroenterol Verh, 24:60-5. IF: anteiliger IF: 0, Schmoll HJ, (1989) The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes. EUR J CANCER CLON ONCOL, 25:35-9. IF: 5,536 anteiliger IF: 5, Summe Bewertung = 10,83483 Summe IF = 15, Harstrick A, Casper J, Kohne-Wompner H, Wilke H, Schmoll HJ, Poliwoda H: (1990) Comparative activity of four anthracyclines against heterotransplanted germ cell tumor lines. INVEST NEW DRUG, 8: S IF: 3,357 anteiliger IF: 0, Harstrick A, Schmoll HJ, Casper J, Wilke H, Poliwoda H: (1990) Activity of cytostatic drugs in two heterotransplanted human testicular cancer cell lines with different sensitivity to standard agents. EUR J CANCER, 26: IF: 5,536 anteiliger IF: 0, Harstrick A, Schmoll HJ, Wilke H, Schober C, Stahl M, Wompner CK, Bokemeyer C, Dolken G, Burk K, Poliwoda H: (1990) High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: a phase II study. ANN ONCOL, 1: IF: 3, anteiliger IF: 0, Jackle-Meyer I, Gwinner W, Baum M, Soose M, Petzoldt R, Schmoll HJ, Stolte H: (1990) Significance of Tamm-Horsfall protein excretion in diabetes mellitus and cisplatin nephrotoxicity. CONTRIB NEPHROL, 83: IF: 1,487 anteiliger IF: 0, Preusser P, Wilke H, Achterrath W, Lenaz L, Stahl M, Casper J, Meyer HJ, Meyer J, Blum M, Schmoll HJ: (1990) Phase II study of carboplatin in untreated inoperable advanced stomach cancer. EUR J CANCER, 26:

7 IF: 5,536 anteiliger IF: 1, Schmoll HJ: (1990) Progress in treatment of testicular cancer. J CANCER RES CLIN, 116: IF: 2,558 anteiliger IF: 2, Schmoll HJ, Harstrick A, Kohne-Wompner CH, Schober C, Wilke H, Poliwoda H: (1990) Modulation of cytotoxic drug activity by dipyridamole. Cancer Treat Rev, 17: IF: 6,054 anteiliger IF: 2, Tesch H, Furbass R, Casper J, Lyons J, Bartram CR, Schmoll HJ, Bronson DL: (1990) Cellular oncogenes in human teratocarcinoma cell lines. INT J ANDROL, 13: IF: 3,591 anteiliger IF: 0, Summe Bewertung = 7,65489 Summe IF = 28, Harstrick A, Schmoll HJ, Bokemeyer C, Metzner B, Illiger HJ, Berdel W, Ostermann H, Manegold C, Rath U, Siegert W, et A: (1991) Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with faradvanced testicular carcinoma. J CANCER RES CLIN, 117: S IF: 2,558 anteiliger IF: 0, Harstrick A, Schmoll HJ, Kohne-Wompner CH, Bergmann L, Lammers U, Hohnloser J, Dolken G, Reichhardt P, Siegert W, Natt F, et A: (1991) Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma. ANN ONCOL, 2: IF: 4,425 anteiliger IF: 0, Harstrick A, Schmoll HJ, Wilke H, Kohne-Wompner CH, Stahl M, Schober C, Casper J, Bruderek L, Schmoll E, Bokemeyer C, et A: (1991) Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J CLIN ONCOL, 9: IF: 1,41, anteiliger IF: 0, Schmoll E, Wilke H, Thole R, Preusser P, Wildfang I, Schmoll HJ: (1991) Megestrol acetate in cancer cachexia. SEMIN ONCOL, 18(1 Suppl 2): IF: 3,5 anteiliger IF: 1, Schmoll HJ: (1991) How should we treat disseminated seminoma? ANN ONCOL, 2: IF: 1,917 anteiliger IF: 1,917

8 41. Schmoll HJ: (1991) Introduction: the clinical challenge. EUR J CANCER, 27: S IF: 5,536 anteiliger IF: 5, Schuppert F, Scheumann GFW, Schöber C, Overbeck J, Schürmeyer T, Schmoll HJ, Dralle H, von zur Mühlen A: (1991) Therapie eines malignen sympathischen Paraganglioms des Zuckerkandlschen Organs - ein Fallbericht. KLIN WOCHENSCHR, 69: IF: 0,809 anteiliger IF: 0, Wilke H, Preusser P, Stahl M, Harstrick A, Meyer HJ, Achterrath W, Schmoll HJ, Seeber S: (1991) Etoposide, folinic acid, and 5-fluorouracil in carboplatinpretreated patients with advanced gastric cancer. CANCER CHEMOTH PHARM, 29: IF: 2,833 anteiliger IF: 0, Wilke H, Preusser P, Fink U, Meyer HJ, Schmoll HJ, Stahl M, Seeber S, (1991) Modern therapeutic strategies in stomach cancer. Z GASTROENTEROL VERH, 26:217-8 IF:0,896, anteiliger IF: 0, Summe Bewertung = 9,24378 Summe IF = 23, Bokemeyer C, Freund M, Schmoll HJ, Rieder H, Fonatsch C: (1992) Secondary lymphoblastic leukemia following treatment of a malignant germ cell tumour. ANN ONCOL, 3: IF: 6,425 anteiliger IF: 0, Bokemeyer C, Harstrick A, Schmoll HJ, Kohne-Wompner CH, Schoffski P, Poliwoda H: (1992) Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas. ANN ONCOL, 3: IF: 6,425 anteiliger IF: 0, Bokemeyer C, Harstrick A, Schoffski P, Schmoll HJ, Poliwoda H: (1992) [Germ-cell tumors of the testis. The epidemiological and etiological aspects]. Dtsch Med Wochenschr, 117: IF: 0,528 anteiliger IF: 0, Galanski M, Schmoll E, Reichelt S, Bohmer G, Prokop M, Schaefer C, Schuler A, Ringe B, Schmidt FW, Schmoll HJ: (1992) [Chemoembolization of hepatocellular carcinoma in cases of isolated liver involvement]. RADIOLOGE, 32: IF: 0,611 anteiliger IF: 0, Harstrick A, Bokemeyer C, Preusser P, Kohne-Wompner CH, Meyer HJ, Stahl M, Knipp H, Schmoll HJ, Wilke H: (1992) Phase II study of single-agent

9 etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. CANCER CHEMOTH PHARM, 29: IF: 3,5 anteiliger IF: 0, Kohne-Wompner CH, Schmoll HJ, Harstrick A, Rustum YM: (1992) Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. SEMIN ONCOL, 19(2 Suppl 3): IF: 3,5 anteiliger IF: 0, Schmoll HJ, Bokemeyer C, Harstrick A, Illiger HJ, Metzner B, Ruther U, Osternamm A, Preiss J, Wilke H, Hohnloser J, et A: (1992) Dose escalation of cisplatin (P), etoposide (E), and ifosfamide (I) with GM-CSF for advanced germ cell tumors. PATHOL BIOL, 39: IF: 1,528 anteiliger IF: 0, Schmoll HJ, Hiddemann W, Rustum Y, Kohne-Wompner CH: (1992) The emerging role for biomodulation of antineoplastic agents. SEMIN ONCOL, 19(2 Suppl 3): IF: 2,194 anteiliger IF: 0, Schmoll HJ, Kohne-Wompner CH, Hiddemann W, Knipp H, Wilke H, Bodenstein H, Schoffski P, Bokemeyer C, Lohrmann HP, Preiss J, et A: (1992) Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial. SEMIN ONCOL, 19(2 Suppl 3): IF: 2,194 anteiliger IF: Schober C, Bokemeyer C, Stahl M, Wilke HJ, Schmoll HJ, Poliwoda H: (1992) The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer. SEMIN ONCOL, 19(2 Suppl 3): IF: 2,194 anteiliger IF: 0, Schober C, Kohne-Wompner CH, Schmoll HJ, Stahl M, Wilke HJ, Poliwoda H: (1992) A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation. SEMIN ONCOL, 19(2 Suppl 3): IF: 2,194 anteiliger IF: 0, Schober C, Schmoll E, Schmoll HJ, Poliwoda H, Schuppert F, Stahl M, Bokemeyer C, Wilke H, Weiss J: (1992) Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours. EUR J CANCER, 28: IF: 2,191 anteiliger IF: 0, Stahl M, Wilke HJ, Seeber S, Schmoll HJ: (1992) Cytokines and cytotoxic agents in renal cell carcinoma: a review. SEMIN ONCOL, 19(2 Suppl 4): IF: 2,194 anteiliger IF: 0, Stahl M, Wilke H, Schmoll HJ, Schober C, Diedrich H, Casper J, Freund M, Poliwoda H: (1992) A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma. ANN ONCOL, 3:

10 IF: 1,917 anteiliger IF: 0, Wilke H, Stahl M, Schmoll HJ, Preusser P, Fink U, Meyer HJ, Achterrath W, Knipp H, Kohne-Wompner CH, Harstrick A, et A: (1992) Biochemical modulation of 5-fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer. SEMIN ONCOL, 19(2 Suppl 3): IF: 2,194 anteiliger IF: 0, Summe Bewertung = 5,37004 Summe IF = 34, Bokemeyer C, Kuczyk M, Schoffski P, Schmoll HJ: (1993) Familial occurrence of Leydig cell tumors: a report of a case in a father and his adult son. J UROLOGY, 150(5 Pt 1): IF: 0,105 anteiliger IF: 0, Bokemeyer C, Luer M, Schmoll HJ, Freund M, Poliwoda H: (1993) Secondary cancer following Hodgkin's disease. ANN ONCOL, 4: IF: 1,917 anteiliger IF: 0, Bokemeyer C, Schmoll HJ: (1993) Secondary neoplasms following treatment of malignant germ cell tumors. J CLIN ONCOL, 11: IF: 0,561 anteiliger IF: 0, Bokemeyer C, Schmoll HJ: (1993) Treatment of advanced germ cell tumours by dose intensified chemotherapy with haematopoietic growth factors or peripheral blood stem cells (PBSC). Eur Urol, 23: 223-9; discussion IF: 8,493 anteiliger IF: 4, Bokemeyer C, Schmoll HJ: (1993) Treatment strategies in metastatic testicular cancer. Eur Urol, 23: IF: 1,959 anteiliger IF: 0, Bokemeyer C, Schmoll HJ, Harstrick A: (1993) Side-effects of GM-CSF treatment in advanced testicular cancer. EUR J CANCER, 29: IF: 1,959 anteiliger IF: 0, Bokemeyer C, Schmoll HJ, Harstrick A, Illiger HJ, Metzner B, Rath U, Hohnloser J, Clemm C, Berdel W, Siegert W, et A: (1993) A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. EUR J CANCER, 29: IF: 1,41, anteiliger IF: 0, Bokemeyer C, Schmoll HJ, Metzner B, Beyer J, Illiger HJ, Kneba M, Ostermann H, Kynast B, Rath U, Poliwoda H: (1993) Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular

11 cancer. ANN HEMATOL, 67: IF: 1,959, anteiliger IF: 0, Bokemeyer C, Schmoll HJ, Schoffski P, Harstrick A, Bading M, Poliwoda H: (1993) Bilateral testicular tumours: prevalence and clinical implications. EUR J CANCER, 29: IF: 1,959 anteiliger IF: 0, Erlichman C, Fine S, Kerr I, Hoffman W, Gorg C, Schmoll HJ, Preusser P, Senn HJ, Gustavsson B: (1993) Experience with 5FU + L-leucovorin. ADV EXP MED BIOL, 339: 77-9; discussion IF: 0,561 anteiliger IF: 0, Grigor KM, Schmoll HJ: (1993) How should we identify high risk testicular tumour patients? Round table discussion. Eur Urol, 23: IF: 1,307 anteiliger IF: 0, Grigor KM, Schmoll HJ: (1993) Should high dose chemotherapy with, or without, autologous bone marrow transplant be included in the primary treatment of testicular cancer? Round table discussion. Eur Urol, 23: IF: 0,561 anteiliger IF: 0, Grundner-Culemann E, Bokemeyer C, Neubauer V, Shalitin C, Schmoll HJ, Poliwoda H, Benter T: (1993) Analysis of a non-ras 21-kDa protein in patients with metastatic testicular germ-cell tumors. J CANCER RES CLIN, 119: IF: 1,041 anteiliger IF: 0, Harstrick A, Bokemeyer C, Scharnofkse M, Hapke G, Reile D, Schmoll HJ: (1993) Preclinical activity of a new platinum analogue, lobaplatin, in cisplatinsensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines. CANCER CHEMOTH PHARM, 33: IF: 1,041 anteiliger IF: 0, Harstrick A, Bokemeyer C, Schmoll HJ, Kohne-Wompner CH, Knipp H, Schoffski P, Anagnou J, Wipperman B, Neumann S, Poliwoda H: (1993) A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as firstline therapy for metastatic soft-tissue sarcoma in adults. CANCER CHEMOTH PHARM, 31: S IF: 2,833 anteiliger IF: 0, Harstrick A, Schmoll HJ, Sass G, Poliwoda H, Rustum Y: (1993) Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines. EUR J CANCER, 29: IF: 1,959 anteiliger IF: 0, Kohne-Wompner CH, Schmoll HJ: (1993) 5-Fluorouracil modulation in colorectal carcinoma experience of German investigators. ADV EXP MED BIOL, 339: IF: 1, anteiliger IF: 0,5

12 77. Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, Oellerich M, Schauer A: (1993) Determination of a fragment of the c-erbb-2 translational product p185 in serum of breast cancer patients. J CANCER RES CLIN, 119: IF: 1,307 anteiliger IF: 0, Schmoll HJ, Harstrick A, Bokemeyer C, Dieckmann KP, Clemm C, Berdel WE, Souchon R, Schober C, Wilke H, Poliwoda H: (1993) Single-agent carboplatinum for advanced seminoma. A phase II study. CANCER-AM CANCER SOC, 72: IF: 2,429 anteiliger IF: 0, Schmoll HJ, Seeber S: (1993) [Current developments in chemotherapy of advanced testicular tumors]. Urologe A, 32: IF: 0,36 anteiliger IF: 0, Schmoll HJ (1993) Management of eary stages of testicular carcinoma: the current status. RECENT RESULTS CANCER RES, 126: IF: 0,952, anteiliger IF: 0, Bokemeyer C, Schmoll H, Harstrick A, Kohnewompner H, Poliwoda H. Treatment of adult osteosarcoma - single-center results in 47 patients. Int J Oncol Nov;3(5): IF: 1,181 anteiliger IF: 0, Bokemeyer C 1, Schmoll H, Casper J, Kuczyk M, Poliwoda H. No growthstimulation of heterotransplanted human testicular cancer cell-lines by recombinant human granulocyte-macrophage colony-stimulating factor (gmcsf). Int J Oncol Jul;3(1): IF: 1,181 anteiliger IF: 0, Bokemeyer C 1, Frank B, Schoffski P, Poliwoda H, Schmoll H. Phantom sensations after orchiectomy for testicular cancer. Int J Oncol Apr;2(4): IF: 1,181 anteiliger IF: 0, Bokemeyer C 1, Harstrick A, Gonnermann O, Schober C, Kuczyk M, Poliwoda H, Schmoll H. Metastatic leydig-cell tumors of the testis - report of 4 cases and review of the literature. Int J Oncol Feb;2(2):241-4.

13 IF: 1,181 anteiliger IF : 0, Summe Bewertung = 12,02088 Summe IF = 40, Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1994) Treatment intensification in disseminated germ-cell tumors. World J Urol, 12: IF: 0,561, anteiliger IF: 0, Bokemeyer C, Dunn T, Harstrick A, Lerch T, Poliwoda H, Schmoll HJ: (1994) Modulation of cytostatic drugs by nifedipine in two heterotransplanted human testicular-cancer cell lines differing in their sensitivity to standard agents. Int J Cancer, 56: IF: 3,276, anteiliger IF: 1, Bokemeyer C, Harstrick A, Ruther U, Metzner B, Illiger HJ, Clemm C, Siegert W, Link H, Ostermann H, Schmoll HJ: (1994) The role of granulocytemacrophage colony-stimulating factor in the treatment of germ cell tumors. German Testicular Cancer Study Group. SEMIN ONCOL, 21(6 Suppl 16): IF: 2,628, anteiliger IF: 0, Bokemeyer C, Harstrick A, Schmoll HJ: (1994) The use of carboplatin in malignant germ cell tumours. EUR J CANCER, 30: IF: 0,789, anteiliger IF: 0, Bokemeyer C, Schmoll HJ, Ludwig E, Harstrick A, Dunn T, Casper J: (1994) The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna. BRIT J CANCER, 69: IF: 3,188, anteiliger IF: 0, Bokemeyer C, Schmoll HJ, Natt F, Knoche M, Beyer J, Souchon R: (1994) Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J CANCER RES CLIN, 120: IF: 1,654, anteiliger IF: 0, Bokemeyer C, Schmoll HJ, Poliwoda H: (1994) [Secondary leukemias after etoposide chemotherapy]. Dtsch Med Wochenschr, 119: IF: 0,605, anteiliger IF: 0, Bokemeyer C, Schmoll HJ, van Rhee J, Kuczyk M, Schuppert F, Poliwoda H: (1994) Long-term gonadal toxicity after therapy for Hodgkin's and non- Hodgkin's lymphoma. ANN HEMATOL, 68: IF: 1,496, anteiliger IF: 0,12469

14 93. Derigs HG, Huber C, Schmoll HJ: (1994) [Stage-oriented therapy in nonseminomatous testicular tumors]. Dtsch Med Wochenschr, 119: IF: 0,605, anteiliger IF: 0, Hill BT, Shellard SA, Fichtinger-Schepman AM, Schmoll HJ, Harstrick A: (1994) Differential formation and enhanced removal of specific cisplatin-dna adducts in two cisplatin-selected resistant human testicular teratoma sublines. ANTI-CANCER DRUG, 5: IF: 1,258, anteiliger IF: 0, Kohne-Wompner CH, Schoffski P, Schmoll HJ: (1994) Adjuvant therapy for colon adenocarcinoma: current status of clinical investigation. ANN ONCOL, 5: IF: 1,914, anteiliger IF: 0, Link H, Herrmann F, Welte K, Aulitzky WE, Ganser A, Kern WV, Meyer P, Schrappe M, Schmoll HJ, Werdan K, et A: (1994) [Rational therapy with G- CSF and GM-CSF]. Med Klin Intensivmed Notfmed, 89: IF: 0,5 anteiliger IF: 0, Schmoll HJ: (1994) [Adjuvant chemotherapy in rectal cancer]. CHIRURG, 65: IF: 0,657, anteiliger IF: 0, Schmoll HJ: (1994) Colorectal carcinoma: current problems and future perspectives. ANN ONCOL, 5: IF: 1,914, anteiliger IF: 1, Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll HJ, Huhn D: (1994) High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J CLIN ONCOL, 12: IF: 7,507, anteiliger IF: 0, Casper J 1, Casper S, Kohnewompner C, Bokemeyer C, Hecker H, Schmoll H. 5-ht3 antagonist ondansetron for the treatment of chemotherapyinduced nausea and vomiting in an outpatient population. Int J Oncol Jun;4(6): IF:1,181 anteiliger IF: 0, Summe Bewertung = 7,33206 Summe IF = 29,733

15 101. Bajorin DF, Nichols CR, Schmoll HJ, Kantoff PW, Bokemeyer C, Demetri GD, Einhorn LH, Bosl GJ: (1995) Recombinant human granulocytemacrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. J CLIN ONCOL, 13: IF: 6,922, anteiliger IF: 0, Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ: (1995) Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. EUR J CANCER, 31: IF: 2,095, anteiliger IF: 0, Bokemeyer C, Kynast B, Harstrick A, Laage E, Schmoll E, von Wussow P, Schmoll HJ: (1995) No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma. CANCER CHEMOTH PHARM, 35: IF: 1,598, anteiliger IF: 0, Bokemeyer C, Ludwig E, Reile D, Harstrick A, Poliwoda H, Schmoll HJ: (1995) Antitumour activity and toxicity of continuous infusion versus bolus administration of bleomycin in two heterotransplanted human testicular cancer cell lines. Oncol Rep, 2: IF: 0,421, anteiliger IF: 0, Bokemeyer C, Schmoll HJ: (1995) Treatment of testicular cancer and the development of secondary malignancies. J CLIN ONCOL, 13: IF: 6,922, anteiliger IF: 3, Bokemeyer C, Schmoll HJ: (1995) Sekundärneoplasien nach der Therapie maligner Keimzelltumoren des Hodens. Strahlenther Onkol, 6: IF: 2,5 anteiliger IF: 1, Bokemeyer C, Schmoll HJ, Kuczyk MA, Beyer J, Siegert W: (1995) Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. JNCI-J NATL CANCER I, 87: IF: 10,165, anteiliger IF: 1, Köhne CH, Hiddemann W, Schüller J, Weiss J, Lorhmann HP, Schmitz- Hübner U, Bodenstein H, Schöber C, Wilke H, Grem J, Schmoll HJ: (1995) Failure of orally administered Dipyridamole to enhance the antineoplastic activity for Fluorouracil in combination with Leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. J CLIN ONCOL, 13: IF: 6,922, anteiliger IF: 2, Köhne CH, Schmoll HJ: (1995) Therapiestudien zur adjuvanten und palliativen Therapie. ONKOLOGE, 1: IF: 0,173 anteiliger IF: 0,0865

16 110. Köhne CH, Schmoll HJ, Wilke H, Käufer C, Rauschecker H, Andreesen R, Ohl U, Lange HJ, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Bade J, Strohmeyer G, Schöffski P, Schubert U, Hecker H: (1995) Interferonalpha does not improve the antineoplastic efficacy of high-dose infusional 5- fluorouracil plus folinic acid in advanced colorectal cancer: First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). ANN ONCOL, 6: IF: 2,256, anteiliger IF: 0, Kuczyk MA, Bokemeyer C, Fichna B, Truss M, Schmoll HJ, Jonas U: (1995) [Differentiated teratoma as late recurrence of metastatic nonseminomatous testicular germ cell tumor. Case report and clinical problems]. Urologe A, 34: IF: 0,381, anteiliger IF: 0, Kuczyk MA, Bokemeyer C, Schmoll HJ, Jonas U: (1995) The prognostic role of alterations of the p53 tumor suppressor gene in superficial and advanced stage bladder cancer. Onkologie, 18: IF: 0,462, anteiliger IF: 0, Rhomberg W, Schmoll HJ, Schneider B: (1995) High frequency of metalworkers among patients with seminomatous tumors of the testis: a casecontrol study. AM J IND MED, 28: IF: 0,987, anteiliger IF: 0, Thiel I, Schmoll HJ, Bokemeyer C: (1995) Primary osteogenic sarcoma of the breast: Report of a case and a short review of the literature. Onkologie, 18: IF: 0,462, anteiliger IF: 0, Bokemeyer C 1, Kuczyk M, Fichna B, Jonas U, Poliwoda H, Schmoll H. Late relapse of testicular cancer presenting as differentiated teratoma - report of a case and discussion of the clinical implications. Oncol Rep Jul;2(4): IF:0,407 anteiliger IF:0, Summe Bewertung = 10,76778 Summe IF = 42, Andrews PW, Casper J, Damjanov I, Duggan-Keen M, Giwercman A, Hata JI, von Keitz A, Looijenga LHJ, Millan JL, Oosterhuis JW, Pera M, Sawada M, Schmoll HJ, Skakkebaek NE, van Putten W, Stern P: (1996) Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumors. Int J Cancer, 66: IF: 3,534, anteiliger IF: 0,08416

17 117. Berger C, Bokemeyer C, Schuppert F, Schmoll HJ: (1996) Endocrinological late effects after chemotherapy for testicular cancer. BRIT J CANCER, 73: IF: 3,666, anteiliger IF: 1, Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1996) Hochdosischemotherapie bei Hodentumoren. ONKOLOGE, 2: IF: 0,173 anteiliger IF: 0, Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W: (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J CLIN ONCOL, 14: IF: 7,881, anteiliger IF: 0, Beyer J, Kramer A, Mandanas R, Linkesch W, Greinix A, Droz JP, Culine S, Diehl A, Bokemeyer C, Schmoll HJ, Einhorn LH, Nichols CR, Siegert W: (1996) Treatment outcome of high-dose chemotherapy as salvage treatment in male germ cell tumors: a multivariate analysis of prognostic factors. J CLIN ONCOL, 14: IF: 7,881, anteiliger IF: 0, Bokemeyer C, Beyer J, Metzner B, Rüther U, Weißbach L, Köhrmann U, Verbeek W, Harstrick A, Schmoll HJ: (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory cancer. ANN ONCOL, 7: IF: 2,736, anteiliger IF: 0, Bokemeyer C, Fels LM, Dunn TA, Voigt W, Gaedeke J, Schmoll HJ, Stolte H: (1996) Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide antitumor activity. BRIT J CANCER, 74: IF: 3,666, anteiliger IF: 0, Bokemeyer C, Köhrmann O, Tischler J, Weißbach L, Räth U, Haupt A, Schöffski P, Schmoll HJ: (1996) A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with good risk metastatic non-seminomatous germ cell tumors. ANN ONCOL, 7: IF: 2,736, anteiliger IF: 0, Bokemeyer C, Kuczyk MA, Dunn TA, Serth T, Hartmann K, Jonasson J, Jonas U, Schmoll HJ: (1996) Expression of stem cell factor and its receptor c- kit protein in normal testicular tissue and malignant germ-cell tumors. J CANCER RES CLIN, 122: IF: 1,093, anteiliger IF: 0, Bokemeyer C, Kuczyk MA, Köhne CH, Einsele H, Kynast B, Schmoll HJ: (1996) Hematopoetic growths factors and treatment of testicular cancer: Biological interactions routine use and dose-intensive chemotherapy. ANN HEMATOL, 72: 1-9 IF: 1,206, anteiliger IF: 0,40196

18 126. Bokemeyer C, Kuczyk MA, Köhne H, Einsele H, Kynast B, Schmoll HJ: (1996) Treatment of testicular cancer and hematopoietic growth factors: Biological interactions routine use and dose-intensive chemotherapy. ANN HEMATOL, 7: 1-9 IF: 1,206, anteiliger IF: 0, Bokemeyer C, Kuczyk MA, Köhne H, Haupt A, Schmoll HJ: (1996) Das Risiko sekundärer Neoplasien nach Behandlung maligner Keimzelltumoren des Hodens. Med Klin Intensivmed Notfmed, 91: IF: 0,468 anteiliger IF: 0, Bokemeyer C, Kuczyk MA, Serth, Hartmann JT, Schmoll HJ, Jonas U, Kanz L: (1996) Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters. J CANCER RES CLIN, 122: IF: 1,093, anteiliger IF: 0, Bokemyer C, Berger C, Kuczyk MA, Schmoll HJ: (1996) Evaluation of long-term toxicity after chemotherapy for testicular cancer. J CLIN ONCOL, 14: IF: 7,881, anteiliger IF: 2, Borchard E, Engelhardt, Frommhold, Hartung, Hermanek, Herrmann, Hossfeld, Junginger, Kirchner, Kreuser, Meyer, Müller, Pichlmaier, Queißer, Schlag, Schmoll, Stock, Wilke: (1996) Konsens der CAO, AOI und ARO zur Diagnostik und Therapie des primären Magenlymphoms. Onkologie, 19: IF: 0,451, anteiliger IF: 0, Dunn TA, Schmoll HJ, Grünwald V, Bokemeyer C, Casper J: (1996) Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer. ANTI-CANCER DRUG, 7: 1-5 IF: 1,397, anteiliger IF: 0, Erlichman C, Fine S, Kerr I, Hoffmann W, Görg C, Schmoll HJ, Preusser P, Thuerlimann B, Gustavsson B: (1996) A phase II trial of 5- fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. AM J CLIN ONCOL-CANC, 19: IF: 0,921, anteiliger IF: 0, Fels LM, Bokemeyer C, van Rhee J, Schmoll HJ, Stolte H: (1996) Evaluation of late nephrotoxicity in long-term survivors of Hodgkin's disease. ONCOLOGY-BASEL, 53: IF: 2,097, anteiliger IF: 0, Hartmann JT, Thiel I, Schmoll HJ, Einsele H, Kanz L, Bokemeyer C: (1996) Malignant fibrous histiocytoma of bone - review of thirteen cases. Oncol Rep, 3: 1-5 IF: 0,476, anteiliger IF: 0, Rambusch EG, Schuppert F, Müller-Kunert E, Stöcker W, Bokemeyer C, Schmoll HJ, von zur Mühlen A: (1996) Zytokintherapie und Endokrinium: Ist es sinnvoll, mehr als die Schilddrüse zu untersuchen? Med Klin

19 Intensivmed Notfmed, 91: IF: 0,468 anteiliger IF: 0, Rüther U, Nunnensiek C, Sessler R, Stilz S, Ulshöfer T, Müller HAG, Bader H, Bokemeyer C, Schmoll HJ, Toomes H, Jipp P: (1996) Efficacy of antiestrogen treatment in a benign metastasizing leimyoma with paraneoplastic estradiol production. Oncol Rep, 3: IF: 0,476, anteiliger IF: 0, Schmoll HJ: (1996) Die Therapie von Keimzelltumoren: Modell für eine interdisziplinäre Behandlungsstrategie. Med Klin Intensivmed Notfmed, 3: IF: 1,709 anteiliger IF: 1, Schmoll HJ: (1996) Development of Treatment for Advanced Colorectal Cancer: Infusional 5-FU and the role of new agents. EUR J CANCER, 32: S18-22 IF: 2,017, anteiliger IF: 2, Schmoll HJ, Bokemeyer C: (1996) Sequential intermediate high-dose chemotherapy in the primary treatment of poor risk testicular cancer. BONE MARROW TRANSPL, 18: IF: 2,771, anteiliger IF: 1, Hartmann J 1, Thiel I, Schmoll H, Einsele H, Kanz L, Bokemeyer C. Malignant fibrous histiocytoma of bone - Review of thirteen cases. Oncol Rep Sep;3(5): IF: 0,407 anteiliger IF: 0, Summe Bewertung = 14,02106 Summe IF = 50, Bamberg M, Schmoll HJ, Weißbach L, Beyer J, Bokemeyer C, Harstrick A, Höltl W, Souchon R, Vogler H: (1997) An interdiciplinary consensus conference on the diagnosis and therapy of testicular tumors. Strahlenther Onkol, 173: IF: 2,5 anteiliger IF: 0, Berkovic D, Grundel O, Berkovic K, Wildfang I, Hess CF, Schmoll HJ: (1997) Synergistic cytotoxic effects of either phospholipid analogues and ionizing radiation in human carcinoma cells. Radiother Oncol, 43: IF: 1,924, anteiliger IF: 0,64127

20 143. Bokemeyer C, Franzke A, Hartmann JT, Schöber C, Arseniev L, Metzner B, Link H, Kanz L, Schmoll HJ: (1997) A Phase I/ II Study of Sequential, Dose-Escalated, High-Dose Ifosfamide plus Doxorubicin with Peripheral Blood Stem Cell Support for the Treatment of Patients with Advanced Soft Tissue Sarcomas. CANCER-AM CANCER SOC, 6: IF: 3,296, anteiliger IF: 1, Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne H, Hartmann JT, Kanz L, Schmoll HJ: (1997) Treatment of brain metastases in patients with testicular cancer. J CLIN ONCOL, 15: IF: 7,878, anteiliger IF: 2, Dunn TA, Schmoll HJ, Grünewald V, Bokemeyer C, Casper J: (1997) Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. INVEST NEW DRUG, 15: IF: 0,543, anteiliger IF: 0, Dunn T, Schmoll HJ, Grünewald V, Casper J, Bokemeyer C: (1997) Pre-clinical activity of taxol in nonseminomatous germ cell tumor cell lines and nude mouse xenografts. INVEST NEW DRUG, 15: IF: 0,543, anteiliger IF: 0, Harstrick A, Köhne CH, Hiddemann W, Preusser P, Berns T, Seeber S, Wilke H, Schmoll HJ: (1997) Modulation of 5-Flourouracil with Metotrexate and Low-dose N-(phosphonacety)-L-aspartete (PALA) in inactive advanced pancreatic carcinoma. ANN ONCOL, 8: IF: 2,548, anteiliger IF: 0, Hartmann JT, Candelaria M, Kuczyk MA, Schmoll HJ, Bokemeyer C: (1997) Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic nonseminomatous germ cell tumors. EUR J CANCER, 33: IF: 2,407, anteiliger IF: 0, Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C: (1997) Postchemotherapy resections of residual masses from metastatic nonseminomatous testicular germ cell tumors. ANN ONCOL, 8: IF: 2,548, anteiliger IF: 0, Hartmannn JT, Schmoll HJ, Thiel I, Kanz L, Bokemeyer C: (1997) Klinische Verlaufsbeobachtung von Patienten mit malignem fibrösen Histiozytom des Knochens und Übersicht zur chemotherapeutischen Behandlung. TUMORDIAGN THER, 1: Jan 34 IF: 0,148, anteiliger IF: 0, Hartmann, Schmoll E, Bokemeyer C, Fety, Lucas, D Agay, Schmoll HJ: (1997) Hepatic arterial infusion of the nitrosourea derivate fotemustine for the treatment of liver metastases from colorectal carcinoma. Oncol Rep, 4: IF: 0,407, anteiliger IF: 0, Köhne C, Harstrick A, Hiddemann W, Schöffski P, Wilke H, Bokemeyer C, Dörken B, Schmoll HJ: (1997) Modulation of 5-Flourouracil with

21 Metotrexate and Low-dose N-(phosphonacety)-L-aspartete in Patients with Advanced Colorectal Cancer. Results of a Phase II Study. EUR J CANCER, 33: IF: 2,407, anteiliger IF: 0, Köhne C, Wilke H, Hiddemann W, Bokemeyer C, Lohrmann HP, Bodenstein H, Preiss J, Rauschecker H, Hill H, Käufer C, Fischer JT, Ohl U, Urbanitz D, Balleisen L, Schmoll HJ: (1997) Phase II Evaluation of 5- Flourouracil plus Folinic acid and alpha 2b-interferon in metastatic colorectal cancer. ONCOLOGY-BASEL, 54: IF: 2,141, anteiliger IF: 0, Malek NP, Casper J, Looijenga LH, Strohmeyer T, Schmoll HJ, Nordheim A, Janknecht R: (1997) Quantification of additional short arms of chromosome 12 in germ cell tumors using the polymerase chain reaction. EUR J CANCER, 33: IF: 2,407, anteiliger IF: 0, Schmoll HJ: (1997) Prognostic factors for advanced seminoma - a solid basis for clinical trials (Editorial). EUR J CANCER, 9: IF: 2,407, anteiliger IF: 2, Schmoll HJ, Bamberg M, Weißbach L: (1997) Interdisziplinäre Konsensus-Konferenz zur Diagnostik und Therapie von Hodentumoren. Onkologie, 20: IF: 0,328, anteiliger IF: 0, Schmoll HJ, Büchele T, Schöber C: (1997) The role of second line chemotherapy in colorectal cancer. Onkologie, 20: IF: 0,328, anteiliger IF: 0, Schöber C, Galanski M, Jörgensen M, Schmoll HJ: (1997) Management of endocrine pancreatic tumors. WIEN KLIN WOCHENSCHR, 147: IF: 0,411, anteiliger IF: 0, Seliger B, Dunn T, Schwenzer A, Casper J, Huber C, Schmoll HJ: (1997) Analysis of the MHC-Class I antigen presentation machinery in a human embryonal carcinoma cell line: evidence for suppression of TAP, LMP and MHC class I expression. SCAND J IMMUNOL, 46: IF: 1,749, anteiliger IF: 0, Weißbach L, Bamberg M, Schmoll HJ: (1997) Interdisciplinary consensus conference on diagnosis and therapy of testicular cancer. Urologe A, 36: IF: 0,513, anteiliger IF: 0, Hartmann J 1, Schmoll E, Bokemeyer C, Fety R, Lucas C, Dagay L, Schmoll H Hepatic arterial infusion of the nitrosourea derivate fotemustine for the treatment of liver metastases from colorectal carcinoma. Oncol Rep Jan-Feb;4(1):

22 IF: 0,407 anteiliger IF: 0, Summe Bewertung = 11,36687 Summe IF = 35, Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1998) Salvagetherapie rezidivierter und refraktärer Hodentumoren. ONKOLOGE, 4: IF: 0,1 anteiliger IF: 0, Beyer J, Schmoll HJ: (1998) Prognosefaktoren bei metastasierten seminomatösen und nichtseminomatösen Hodentumoren. ONKOLOGE, 4: IF: 0,1 anteiliger IF: 0, Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L: (1998) Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. BRIT J CANCER, 77: IF: 3,036, anteiliger IF: 0, Bokemeyer C, Gerl A, Harstrick A, Schmoll HJ: (1998) Therapie des fortgeschrittenen nichtseminomatösen Keimzelltumors. ONKOLOGE, 4: IF: 0,1 anteiliger IF: 0, Bokemeyer T, Harstrick A, Beyer J, Metzner B, Rüther U, Hartmann JT, Holstein K, Derigs HG, de Wit R, Casper J, Schöffski P, Kuhrer I, Illiger HJ, Kempf B, Reichle A, Foller A, Hossfeld DK, Fischer JT, Berdel WE, Gerhartz HH, Kirchner H, Pflüger KH, Ostermann H, Kanz L, Schmoll HJ: (1998) The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. SEMIN ONCOL, 25: IF: 2,252, anteiliger IF: 0, Dunn T, Schmoll HJ, Rie C, Hartmann K, Casper J: (1998) Production and pre-clinical significance of hematopoietic peptide growth factor (HPGF) in human non-seminomatous germ cell tumor (NSGCT) cell lines. J CANCER RES CLIN, 124: IF: 1,183, anteiliger IF: 0, Hartmann JT, Köhne CH, Schmoll HJ, Daikeler T, Kanz L, Bokemeyer C: (1998) Is continuous 24-hour infusion of 5-Flourouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II Study. ONCOLOGY-BASEL, 55: IF: 2,858, anteiliger IF: 0, Hartmann JT, Schmoll E, Bokemeyer C, Fety R, Lucas C, Giroux B, Schmoll HJ: (1998) Phase I Pharmacological Study of Intra-arterially Infused

23 Fotemustine for Colorectal Liver Metastases. EUR J CANCER, 34: IF: 2,743, anteiliger IF: 0, Köhne CH, Schöffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstrick A, Bade J, Horster A, Schubert U, Hecker H, Dörken B, Schmoll HJ: (1998) Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J CLIN ONCOL, 16: IF: 8,228, anteiliger IF: 2, Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P, Flechon A, Schöffski P, Kuczyk M, Schmoll HJ, Kanz L, Bokemeyer C: (1998) Secondary leukemia following high cumulative doses for Etoposide in Patients treated for advanced germ cell tumors. J CLIN ONCOL, 16: IF: 8,228, anteiliger IF: 0, Korfel A, Scheulen ME, Schmoll HJ, Gründel O, Harstrick A, Knoche M, Fels LM, Skorzec M, Bach F, Baumgart J, Saß G, Seeber S, Thiel E, Berdel WE: (1998) Phase I Clinical and Pharmacokinetic Study of Titanocene Dichloride in adults with advanced solid tumors. CLIN CANCER RES, 4: IF: 2,941, anteiliger IF: 0, Schmoll HJ: (1998) Is there a standard adjuvant treatment for colon cancer? (Editorial). EUR J CANCER, 34: IF: 2,743, anteiliger IF: 2, Schmoll HJ: (1998) Is there a standard adjuvant treatment for rectal cancer? (Editorial). EUR J CANCER, 34: IF: 2,743, anteiliger IF: 2, Schmoll HJ, Beyer J: (1998) Prognostic factors in metastatic germ cell tumors. SEMIN ONCOL, 25: IF: 2,252, anteiliger IF: 1, Schmoll HJ, Weißbach L, Bamberg M: (1998) Editorial: Therapie des Hodentumors: das Zauberwort heißt Interdisziplinarität. ONKOLOGE, 4: IF: 0,1 anteiliger IF: 0, Summe Bewertung = 11,94738 Summe IF = 39, Bokemeyer C, Gerl A, Schöffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ: (1999) Gemcitabine in patients with relapsed or Cisplatin-refractory testicular cancer. J CLIN ONCOL, 17: IF: 7,963, anteiliger IF: 2,65407

24 178. Bokemeyer C, Kollmannsberger C, Harstrick A, Beyer J, Gerl A, Casper J, Metzner B, Hartmann JT, Schmoll HJ, Kanz L: (1999) Treatment of patients with Cisplatin-refractory testicular germ-cell cancer. Int J Cancer, 83: IF: 3,545, anteiliger IF: 0, Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C: (1999) First-Line High-Dose Chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J CLIN ONCOL, 17: IF: 7,963, anteiliger IF: 0, Dempke W, Behrmann C, Schöber C, Büchele T, Grothey A, Schmoll HJ: (1999) Diagnostisches und therapeutisches Management der oberen Einflussstauung. Med Klin Intensivmed Notfmed, 94: IF: 0,5 anteiliger IF: 0, Dempke W, Büchele T, Wolf HH, Grothey A, Schmoll HJ: (1999) Diagnostik und Therapie maligner Pleura- und Perikardergüsse. Onkologie, 22: IF: 0,382, anteiliger IF: 0, Dempke W, Voigt W, Grothey A, Schmoll HJ: (1999) Preferential repair of the N-ras gene in K562 cells after exposure to cisplatin. ANTI-CANCER DRUG, 10: IF: 1,594, anteiliger IF: 0, Fossa SD, Bokemeyer C, Gerl A, Culine S, Jones WG, Mrad GM, Germa-Luch JR, Pont J, Schmoll HJ, Tjulandin S: (1999) Treatment outcome of patients with brain metastases from malignant germ cell tumors. CANCER- AM CANCER SOC, 85: IF: 3,632, anteiliger IF: 0, Grothey A, Voigt W, Schöber C, Müller T, Dempke W, Schmoll HJ: (1999) The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J CANCER RES CLIN, 125: IF: 1,052, anteiliger IF: 0, Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, Bokemeyer C: (1999) Long-term effects on sexual function and fertility after treatment of testicular cancer. BRIT J CANCER, 80: IF: 3,282, anteiliger IF: 0, Kellner O, Dempke W, Schmoll HJ: (1999) Glukose-Infusionen - eine mögliche effektive Therapieoption bei der Ifosfamid-induzierten Enzephalopathie. Dtsch Med Wochenschr, 124: IF: 0,684, anteiliger IF: 0, Schmoll HJ: (1999) Treatment of testicular tumours based on risk factors. CURR OPIN UROL, 9: IF: 2,59 anteiliger IF: 2,59

25 188. Schmoll HJ: (1999) Standards in der Behandlung kolorektaler Karzinome - Wunsch und Wirklichkeit. ONCOLOGY-BASEL, 99: 6-7 IF: 2,684, anteiliger IF: 2, Schmoll HJ, Büchele T, Grothey A, Dempke W: (1999) Where do we stand with 5-FU? SEMIN ONCOL, 26: IF: 2,986, anteiliger IF: 0, Summe Bewertung = 8,43815 Summe IF = 35, Brieger P, Wolf HH, Schmoll HJ, Marneros A: (2000) Manic episode in an ifosfamide-treated patient. GEN HOSP PSYCHIAT, 22: IF: 1,512, anteiliger IF: 0, Büchele T, Grothey A, Schmoll HJ: (2000) Neue Perspektiven mit neuen Zytostatika in der Behandlung des kolorektalen Karzinoms. ONKOLOGE, 6: IF: 0,12 anteiliger IF: 0, Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ: (2000) Cisplatin resistance and oncogenes - a review. ANTI-CANCER DRUG, 11: IF: 1,57, anteiliger IF: 0, Dempke W, von Poblozki A, Grothey A, Schmoll HJ: (2000) Human hematopoietic growth factors: old lessons and new perspectives. ANTICANCER RES, 20: IF: 1,331, anteiliger IF: 0, Grothey A, Kegel T, Dempke W, Schmoll HJ: (2000) Systemische Therapie des hepatozellulären Karzinoms. ONKOLOGE, 6: IF: 1,41 anteiliger IF: 0, Kellner O, Voigt W, Schneyer U, Dempke W, Schmoll HJ: (2000) HCGinduced hyperthyreosis in germ cell cancer. ANTICANCER RES, 20: IF: 1,331, anteiliger IF: 0, Kollmannsberger C, Nichols C, Bamberg M, Hartmann JT, Schleucher N, Beyer J, Schöffski P, Gerigs G, Rüther U, Bohlke I, Schmoll HJ, Kanz L, Bokemeyer C: (2000) First-Line High-Dose chemotherapy + radiation therapy in patients with metastatic germ-cell cancer and brain metastases. ANN ONCOL, 11: IF: 3,249, anteiliger IF: 0, Schmiegel W, Adler G, Frühmorgen P, Fölsch U, Greaven U, Layer P, Petrasch S, Porschen R, Pox C, Sauerbruch T, Schmoll HJ, Zeitz M: (2000) Kolorektales Karzinom: Prävention und Früherkennung in der asymptomatischen Bevölkerung - Vorsorge bei Risikopatienten - Endoskopische Diagnostik, Therapie und Nachsorge von Polypen und Karzinomen. Z Gastroenterol, 38: 49-75